# Bayer: Observational study closed enrollment, 4613 enrolled (Chronic Kidney Disease, Type 2 Diabetes Mellitus)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Bayer |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting |
| NCT ID | NCT05348733 |
| Phase | Observational |
| Status | active not recruiting |
| Conditions | Chronic Kidney Disease; Type 2 Diabetes Mellitus |
| Intervention types | drug |
| Target enrollment | 4613 |
| Site countries | United States, Argentina, Belgium, Brazil, Canada, China, Denmark, Germany, Greece, Mexico, Netherlands, Portugal |
| Posted | 2022-04-27 |
| Planned start | 2022-06-13 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-16 |
| Last update posted | 2026-10-16 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 4613 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05348733). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.